In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fred Khosravi & Amar Sawhney: Dynamic Device Development Duo

Executive Summary

Located on opposite coasts and with complementary skill sets, Fred Khosravi, founder of EndoTex, teamed up with Amar Sawhney, founder of Confluent Surgical, to form Incept, which has become a powerful device company creation engine. Using a unique formula that launches new companies building on previous successes, Incept has compiled an enviable record, starting nine companies in 11 years with three exits and no failures.

You may also be interested in...



TAVI Halo Shines On Embolic Protection Devices

Transcatheter heart valve (TAVI) companies are hot. A market that was worth $20-$30 million just two or three years ago, based on devices with an average selling price of $23,000, was worth more than $400 million in 2010, and to date these products are only approved in Europe. A major stumbling block to widespread penetration exists however: the higher risk of stroke seen with TAVI as compared to surgical valve replacement. Thus, investors are spreading the net out further, to scoop up companies developing embolic protection devices, to solve some of the potential neuro problems that can result from TAVI.

TAVI Halo Shines On Embolic Protection Devices

Transcatheter heart valve (TAVI) companies are hot. A market that was worth $20-$30 million just two or three years ago, based on devices with an average selling price of $23,000, was worth more than $400 million in 2010, and to date these products are only approved in Europe. A major stumbling block to widespread penetration exists however: the higher risk of stroke seen with TAVI as compared to surgical valve replacement. Thus, investors are spreading the net out further, to scoop up companies developing embolic protection devices, to solve some of the potential neuro problems that can result from TAVI.

Interview with Fred Khosravi

In Vivo interviews device entrepreneur Fred Khosravi about his secrets for success in medical device company creation. Khosravi was part of the ACS organization that eventually became Guidant, where he was on the leading edge of the coronary stent revolution. That experience provided Khosravi with a broad background in interventional cardiology devices that was useful in starting his first company, carotid stent company EndoTex Interventional Systems (which was acquired by Boston Scientific) and several other successful companies.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel